Most Read

The move supports the indication of a single priming anti-CTLA4 antibody dose added to the human monoclonal antibody Imfinzi (durvalumab) to treat HCC patients. AstraZeneca also submitted a

The drug will be indicated as an adjuvant treatment for NSCLC in adults with a high risk of recurrence with PD-L1≥50% and without EGFR mutant or ALK-positive NSCLC,

Although HCC is the most common type of liver cancer, options to treat the disease are restricted. The total prognosis for survival is poor, with a five-year survival

BenevolentAI is clinical-stage artificial intelligence (AI) enabled drug discovery company, while DNDi) is a not-for-profit research and development (R&D) organisation with focus on neglected diseases., The company focuses

Located in Frederick, Maryland, the 275,000ft2 facility will produce the FDA-approved CAR T-cell therapy which is utilised for the treatment of blood cancer. The CAR T-cell therapies are

As part of the collaboration, the companies will jointly develop new antibody drugs which can significantly expand the immunotherapy’s potential in improving the lives of cancer and other

Bionova Scientific is a portfolio company of private investment firm Great Point Partners. It offers contract process development services as well as GMP-compliant contract manufacturing services to biopharmaceutical

The drug is claimed to be the first and only oral MET inhibitor recommended to treat advanced NSCLC harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping

Padcev is indicated as a monotherapy to treat locally advanced or metastatic urothelial cancer adult patients who previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor. The regulatory